| Today's Big NewsOct 13, 2022 |
| By Nick Paul Taylor GSK was hiding a strong hand in the high-stakes respiratory syncytial virus vaccine game. Having kept its phase 3 results under wraps, the Big Pharma has now released data from the trial—and revealed itself to be a genuine challenger for a market targeted by Pfizer, Johnson & Johnson and Moderna. |
|
|
|
By Andrea Park With less than a week to go until the FDA’s long-awaited rule enabling hearing aids to be sold over the counter takes effect, consumer tech makers are lifting the curtain on their first entries in the brand-new medical device category. |
By Angus Liu Novartis is swinging the layoff ax once again, and this time it’s falling on operations in Dublin. The Swiss pharma is cutting about 400 jobs at its global service center at Elm Park in Dublin by the end of 2024. |
By Dave Muoio Only 10 new transactions were announced during the third quarter of 2022, yet total transacted revenue outpaced that of the last few years' equivalent quarters, according to a new retrospective analysis from Kaufman Hall. |
By James Waldron Relmada Therapeutics’ lead asset has flunked a phase 3 trial in major depressive disorder, plunging the biotech’s stock down 77%. |
By Conor Hale Set to be launched in Europe, the updated portfolio will connect to Roche’s digital Navify Pass, which can store and display test results as well as a person’s vaccination status. |
By Fraiser Kansteiner For copycat drugmaker Alvogen and British Big Pharma AstraZeneca, the cost of allegedly stalling generics to AZ’s cancer drug Zoladex in Korea is just $1.82 million, or 2.6 billion Korean won. That’s the total sum Korea’s Fair Trade Commission fined the companies for their alleged Zoladex plot, local news outlet Yonhap News Agency first reported Thursday. |
By Paige Minemyer Humana is joining forces with USAA to launch a new plan that aims to complement the care veterans receive through the Veterans Administration. |
By Nick Paul Taylor The Odyssey Therapeutics story is progressing quickly. Ten months after disclosing a $218 million series A, the Gary Glick-helmed biotech is back with another mega round as it prepares to push candidates into IND-enabling studies next year. |
By Angus Liu Sanofi has signed a deal to sell a manufacturing site in Japan for an undisclosed amount to German CDMO Adragos Pharma. The buyer intends to further expand the facility's capacity. |
By Andrea Park Most neurostimulation devices can be manually adjusted by users and their caregivers to customize treatments for chronic pain, epilepsy, stroke recovery and more, but an implant newly approved by the FDA outsources some of those tweaks to artificial intelligence. |
By Max Bayer Otonomy had hoped that its hearing loss med could revive clinical aspirations, but phase 2 data of the higher dose groups disappointed. The company reported the dosing levels did not meaningfully improve hearing from baseline compared to placebo. |
By Heather Landi Brave Health developed virtual mental health services to connect Medicaid patients with therapists, psychiatric providers and peer support specialists. The startup nabbed $40 million in fresh cash to expand into markets and build out its technology. |
Fierce podcasts Don't miss an episode |
| This week on "Podnosis," we talk about the trend of retail giants getting involved primary care. Also under discussion is our special report spotlighting the important contributions made by people of color across health systems, physicians' offices, health tech and insurance companies. |
|
|---|
|
|
|
Monday, October 17, 2022 | 11am ET / 8am PT Given the wide array of post transcriptional and post translational regulatory processes that govern cellular dynamics, additional omics types are needed to capture a more comprehensive understanding of the molecular landscape of a tumor.Register now to learn more. 
|
|
eBook Looking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
eBook In this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
eBook With real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
Whitepaper Read about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
Whitepaper SaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
Whitepaper This paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
